v3.25.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
 9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Cash flow from operating activities:        
Net loss $ (44,599,000) $ (205,842,000) $ (196,295,000) $ 14,192,000
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization 6,046,000 7,028,000 9,324,000 9,436,000
Non cash lease expense 125,000 (62,000) (13,000) (59,000)
Deferred income taxes     (1,000)
Provision for credit losses 222,000 456,000 1,233,000 1,877,000
Provision for inventory obsolescence (50,000) 1,328,000
Change in fair value of warrant liabilities 1,156,000 (6,788,000) (6,164,000) (42,109,000)
Inventory impairment     5,384,000 904,000
Goodwill impairment 112,347,000 112,347,000 3,610,000
IPR&D impairment 107,800,000 107,800,000
Stock-based compensation expense 8,628,000 11,442,000 15,017,000 15,856,000
Change in fair value of contingent consideration (104,339,000) (104,339,000) (126,277,000)
Acquired in-process research and development 3,000,000 3,000,000
Issuance of common stock for stem-cells to be used in research and development 1,000,000 1,000,000
Issuance of common stock to Palantir as consideration for settlement agreement 175,000    
Issuance of common stock relating to Yorkville debt extension     712,000
Discounts arising from RWI loan arrangement - related party 2,151,000 2,151,000
Fair value of warrant modification for professional services 403,000 403,000
Change in fair value of debt 694,000 354,000 1,177,000 2,522,000
Change in fair value of contingent stock consideration (159,000) (159,000) 186,000
Other, net (285,000) 2,012,000 4,157,000 (37,000)
Issuance of common stock to Yorkville for debt extension and SEPA commitment fee 317,000 712,000    
Loss on extinguishment of debt 3,908,000    
Non cash interest expense 3,217,000    
Changes in assets and liabilities:        
Accounts receivable 1,054,000 (118,000) (6,827,000) (3,584,000)
Inventory 5,653,000 (1,605,000) (865,000) (16,891,000)
Prepaid expenses and other assets 109,000 2,179,000 5,606,000 49,000
Accounts payable 1,312,000 6,754,000 8,497,000 (2,948,000)
Accrued expenses and other liabilities 7,237,000 1,533,000 (1,128,000) (2,623,000)
Accrued R&D software (3,500,000) 24,161,000 (3,834,000) 7,333,000
Right-of-use assets and lease liabilities     275,000 263,000
Lease liabilities - operating 274,000 172,000    
Deferred revenue 312,000 1,065,000 1,528,000 425,000
Net cash used in operating activities (7,995,000) (34,344,000) (38,685,000) (137,876,000)
Cash flow from investing activities:        
Capital expenditures (105,000) (468,000) (1,048,000) (5,236,000)
Proceeds from Sanuwave convertible note receivable 2,175,000    
Purchase of acquired in-process research and development (3,000,000) (3,000,000)
Net cash provided by (used in) investing activities 2,070,000 (3,468,000) (4,048,000) (5,236,000)
Cash flow from financing activities:        
Proceeds from RWI senior secured bridge loan and warrants - related party     12,375,000 46,491,000
Proceeds from warrants and short-term debt - related parties 15,000,000 18,369,000    
Proceeds from issuance of short-term debt - unaffiliated 2,993,000 2,000,000    
Principal payments of Yorkville short-term debt     (16,811,000)
Proceeds from issuance of senior secured C.V. Starr bridge loan and warrants - related party     4,994,000
Proceeds from short-term debt     39,200,000
Proceeds from the sale of common stock in ATM offering 136,000 136,000 6,519,000
Payments of ATM offering costs and commissions     (498,000)
Repayments of short-term debt - unaffiliated (17,374,000) (16,811,000)    
Payment of SEPA commitment fee (25,000)    
Repayments of short-term debt - related parties (106,000)    
Proceeds from other short-term debt     2,000,000
Proceeds from other short-term debt - related party     1,000,000
Proceeds from PIPE financing 6,000,000 12,750,000 12,750,000 30,000,000
Proceeds from the exercise of stock options 304,000 304,000 862,000
Tax withholding on vesting of restricted stock units (430,000) (87,000) (101,000) (132,000)
Proceeds from registered direct offering 9,000,000 9,000,000
Payments of PIPE and other issuance costs (1,553,000) (1,553,000) (2,604,000)
Net cash provided by financing activities 6,058,000 24,108,000 24,094,000 119,838,000
Net increase (decrease) in cash, cash equivalents and restricted cash 133,000 (13,704,000) (18,639,000) (23,274,000)
Cash, cash equivalents and restricted cash at beginning of period 10,163,000 28,802,000 28,802,000 52,076,000
Cash, cash equivalents and restricted cash at end of period 10,296,000 15,098,000 10,163,000 28,802,000
Supplemental disclosure of cash flow information:        
Cash paid for interest 144,000 1,073,000 1,073,000
Supplemental non-cash investing and financing activities:        
Property and equipment included in accounts payable and accrued expenses (56,000) (752,000) (223,000) (683,000)
Common stock issued for short-term debt conversion 4,599,000 4,599,000 4,099,000
Issuance of warrants on senior secured bridge loan 2,002,000 2,002,000
Reduction of right-of-use assets and associated lease liabilities - operating due to lease modification (2,083,000) (2,083,000)
PIPE related offering costs included in accrued expenses (69,000) (69,000)
Interest accrued on senior secured loans within long-term debt - related parties (1,229,000) (1,770,000)
Reclassification of option liabilities to equity     $ 441,000
Modification of C.V. Starr warrants in connection with forbearance 51,000    
Issuance of RWI warrants in connection with forbearance 1,162,000    
Reclassification of warrants from liability classified to equity classified $ 2,970,000